Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Insilico Out-Licenses Global Rights for USP1 Inhibitor to Exelixis for $80 Million Upfront

publication date: Sep 13, 2023

Insilico Medicine, a Hong Kong-New York AI drug discovery company, out-licensed global rights to a small molecule inhibitor of USP1 for BRCA-mutated tumors to Exelixis of Alameda, California. Exelixis will pay $80 million upfront plus unspecified milestones and royalties. USP1 repairs DNA damage by removing ubiquitin from multiple substrates. Exelixis will also have rights to other Insilico-discovered USP1 candidates. Founded in 2018, Insilico has partnered with US and China biopharmas to discover candidates for specific targets, including a six-drug deal worth up to $1.2 billion with Sanofi. More details....

Stock Symbol: (NSDQ: EXEL)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital